[Hemorheologic, metabolic and blood coagulation changes in diabetics in treatment with sulfanyl ureas].
A study was carried out to see if chronic treatment with a sulphanylurea with hypoglycaemic action, with also haemoactive action in terms of anti-platelet aggregation, profibrinolytic and antifibrinogenetic action also acted haemorheologically. For this purpose a group of patients treated with Gliclazide was compared with a group under treatment with Glibenclamide. A significant variation was noted in terms of an increase in erythrocyte filtrability and a diminution in erythrocyte aggregation with diminution in blood viscosity at low shear-rates. The absence of parallel modifications in quantitative corpuscular viscous factors, the early onset of the process, the real diminution in the sense of a reduction below the range of normality suggests that the effect is pharmacological and not mediated by metabolic compensation.
D001777:Blood Coagulation / Q000187:drug effects*; D001809:Blood Viscosity / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005907:Gliclazide / Q000494:pharmacology* / Q000627:therapeutic use; D005905:Glyburide / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D012212:Rheology; D013453:Sulfonylurea Compounds / Q000494:pharmacology*
D013453:Sulfonylurea Compounds; D005907:Gliclazide; D005905:Glyburide
Modificazioni emoreologiche, metaboliche ed emocoagulative in diabetici in trattamento con sulfaniluree.